CN102391995B - 一种杂交瘤细胞无血清高密度悬浮灌流培养工艺 - Google Patents
一种杂交瘤细胞无血清高密度悬浮灌流培养工艺 Download PDFInfo
- Publication number
- CN102391995B CN102391995B CN 201110377871 CN201110377871A CN102391995B CN 102391995 B CN102391995 B CN 102391995B CN 201110377871 CN201110377871 CN 201110377871 CN 201110377871 A CN201110377871 A CN 201110377871A CN 102391995 B CN102391995 B CN 102391995B
- Authority
- CN
- China
- Prior art keywords
- perfusion
- culture
- cell
- substratum
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010412 perfusion Effects 0.000 title claims abstract description 102
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 20
- 239000000725 suspension Substances 0.000 title claims description 9
- 238000005516 engineering process Methods 0.000 title abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 51
- 230000008569 process Effects 0.000 claims abstract description 45
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 35
- 239000008103 glucose Substances 0.000 claims abstract description 30
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 27
- 239000000758 substrate Substances 0.000 claims abstract description 20
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000006227 byproduct Substances 0.000 claims abstract description 9
- 238000004364 calculation method Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 95
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 34
- 238000012258 culturing Methods 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 21
- 239000004310 lactic acid Substances 0.000 claims description 17
- 235000014655 lactic acid Nutrition 0.000 claims description 17
- 238000011084 recovery Methods 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 238000005273 aeration Methods 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 230000011218 segmentation Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 8
- 230000002503 metabolic effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000004886 process control Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 27
- 230000012010 growth Effects 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HHNFORCFJOVQNF-UHFFFAOYSA-N cyl-1 Chemical compound N1C(=O)C(CCCCCC(=O)C2OC2)NC(=O)C2CCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(OC)C=C1 HHNFORCFJOVQNF-UHFFFAOYSA-N 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 101100441844 Caenorhabditis elegans cyl-1 gene Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 101100382953 Mus musculus Ccnd1 gene Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940116176 remicade Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229940049197 cerezyme Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 108010006578 follitropin alfa Proteins 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940057854 gonal f Drugs 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 108010039650 imiglucerase Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 229940107685 reopro Drugs 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 244000215747 Pachyrhizus erosus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 229940040591 biotech drug Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000003037 histogenic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Product | Company | Year | Sales(SM/year) |
Centoxin | Centocor | 1991 | n/a |
Cerezyme | Genzyme | 1994 | 740 |
ReoPro | Centocor | 1994 | 400 |
Gonal-F | Serono | 1997 | 600 |
Remicade | Centocor | 1998 | 1500 |
ReFacto | Wyeth | 2000 | 224 |
Kogenate-FS | Bayer | 2000 | 424 |
Zigris | Eli Lilly | 2001 | 160 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110377871 CN102391995B (zh) | 2011-11-24 | 2011-11-24 | 一种杂交瘤细胞无血清高密度悬浮灌流培养工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110377871 CN102391995B (zh) | 2011-11-24 | 2011-11-24 | 一种杂交瘤细胞无血清高密度悬浮灌流培养工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102391995A CN102391995A (zh) | 2012-03-28 |
CN102391995B true CN102391995B (zh) | 2012-12-12 |
Family
ID=45859378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110377871 Active CN102391995B (zh) | 2011-11-24 | 2011-11-24 | 一种杂交瘤细胞无血清高密度悬浮灌流培养工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102391995B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102604884B (zh) * | 2012-03-01 | 2014-12-03 | 江苏太平洋美诺克生物药业有限公司 | 细胞的发酵培养方法 |
CN103898041B (zh) * | 2012-12-25 | 2017-09-29 | 深圳先进技术研究院 | 杂交瘤细胞的培养方法 |
DE102014106916A1 (de) * | 2013-05-28 | 2014-12-04 | Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG | Vorrichtung zur automatisierten Bestimmung von mindestens zwei unterschiedlichen Prozessparametern |
WO2016061066A1 (en) * | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
CN109796530A (zh) * | 2017-11-17 | 2019-05-24 | 北京中原合聚经贸有限公司 | 一种杂交瘤细胞过滤灌流培养制备抗体的方法 |
CN109265539A (zh) * | 2018-10-12 | 2019-01-25 | 浙江正熙生物医药有限公司 | 利用杂交瘤细胞生产单克隆抗体的方法及其生产的单克隆抗体 |
SE1930321A1 (en) * | 2019-10-08 | 2021-04-09 | Veronique Chotteau | A method to feed component in perfusion culture |
CN112680396B (zh) * | 2019-10-18 | 2024-04-05 | 东曜药业有限公司 | 单抗或重组蛋白大规模生产中细胞扩增的方法 |
CN110964688B (zh) * | 2019-12-18 | 2022-01-21 | 杭州奕安济世生物药业有限公司 | 动物细胞灌流培养的方法 |
CN112094814B (zh) * | 2020-11-09 | 2021-08-24 | 康希诺生物股份公司 | 一种通过灌流培养工艺制备腺病毒载体疫苗的方法 |
CN112592948B (zh) * | 2020-12-16 | 2023-05-09 | 广州汉腾生物科技有限公司 | 动物细胞的灌流培养方法 |
CN112662551B (zh) * | 2020-12-29 | 2022-02-22 | 上海药明生物医药有限公司 | 一种细胞培养控制方法以及系统 |
CN113528710B (zh) * | 2021-06-28 | 2024-03-19 | 苏州纽博立科技有限公司 | 一种用于抗体药物生产的温度调控方法 |
CN115976145B (zh) * | 2022-11-28 | 2023-06-23 | 广州誉衡生物科技有限公司 | 一种用于生产pd-1抗体的cho细胞高效灌流补料培养方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1158388C (zh) * | 2001-09-29 | 2004-07-21 | 陈志南 | 连续灌流式培养杂交瘤细胞制备抗体的方法 |
CN1238498C (zh) * | 2004-02-12 | 2006-01-25 | 陈志南 | 动物细胞无血清悬浮培养工艺过程控制参数的方法 |
-
2011
- 2011-11-24 CN CN 201110377871 patent/CN102391995B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102391995A (zh) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102391995B (zh) | 一种杂交瘤细胞无血清高密度悬浮灌流培养工艺 | |
Lim et al. | Fed-batch cultures: principles and applications of semi-batch bioreactors | |
Jain et al. | Upstream processes in antibody production: evaluation of critical parameters | |
Sierra et al. | Characterization of a flat plate photobioreactor for the production of microalgae | |
Kurokawa et al. | Growth characteristics in fed‐batch culture of hybridoma cells with control of glucose and glutamine concentrations | |
CN103756886A (zh) | 一种微藻高密度连续培养的方法及其装置 | |
US20200255785A1 (en) | Online biomass capacitance monitoring during large scale production of polypeptides of interest | |
CN103305417A (zh) | 进行蛋白生产的高产量反应器及其生产方法和应用 | |
Pörtner et al. | Advanced process and control strategies for bioreactors | |
García Sánchez et al. | Minimization of carbon losses in pilot‐scale outdoor photobioreactors by model‐based predictive control | |
Kresnowati et al. | Model-based analysis and optimization of bioreactor for hematopoietic stem cell cultivation | |
WO2021008571A1 (zh) | 高密度连续接种的细胞培养方法及其应用 | |
Qin et al. | Open pond culture systems and photobioreactors for microalgal biofuel production | |
CN103298925A (zh) | 用于培养人髓样白血病细胞以及由其衍生的细胞的方法 | |
EP2126036B1 (en) | Biotechnical and microbiological production method and equipment | |
Oosterhuis et al. | How multipurpose is a disposable bioreactor? | |
CN110106139A (zh) | 一种基于Tubespin生物反应器的缩小模型的细胞灌流培养方法 | |
Pörtner et al. | Kinetic studies on hybridoma cells immobilized in fixed bed reactors | |
Malik et al. | Large-Scale Culture of Mammalian Cells for Various Industrial Purposes | |
Alcântara et al. | Evolution and design of continuous bioreactors for the production of biological products | |
Harada et al. | Fermentation pilot plant | |
CN108220379A (zh) | 一种杂交瘤细胞生产单克隆抗体的方法 | |
Carvajal et al. | Simulation of the batch fermentation stage in the process to obtain ethanol from final molasse | |
CN102604884B (zh) | 细胞的发酵培养方法 | |
Yun et al. | Continuous stable production of von Willebrand Factor monoclonal antibody in spin filter bioreactor with bleeding technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: CHEN ZHINAN Effective date: 20140930 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140930 Address after: 710032 Changle West Road, Shaanxi, China, No. 17, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032 Changle West Road, Shaanxi, China, No. 17, No. Patentee before: Chen Zhinan |